Drake, Ozempic, and Type 2 Diabetes: How a Regular Patient Gets Access to GLP-1 and Insulin Therapy

What Drake Actually Said About Ozempic

Drake's reference to Ozempic was brief and lyrical, not a medical disclosure. In the 2023 song "Rich Baby Daddy" (featuring SZA and Sexyy Red), he included the line in a context that many listeners interpreted as a self-aware nod to celebrity weight-loss culture. He has not given any interview or social post confirming personal use of semaglutide, insulin, or any diabetes medication.

What the Public Record Shows

Photos from 2022 to 2024 showed changes in Drake's build that generated widespread online speculation. Journalists and fans attributed the shift variously to diet, training, or pharmaceutical intervention. None of these conclusions are supported by a primary source. Any claim that Drake uses Ozempic, insulin, or any specific medication is inference, not confirmed fact.

Why the Reference Still Matters Clinically

The lyric landed because Ozempic had already become a cultural shorthand for rapid, medically assisted weight loss. That cultural moment has a real clinical underpinning. Semaglutide (the active molecule in Ozempic and Wegovy) produced a mean 14.9% reduction in body weight at 68 weeks versus 2.4% with placebo in the STEP-1 trial (N=1,961) [1]. That is not a minor effect. For patients with type 2 diabetes (T2D), the SUSTAIN-6 trial (N=3,297) showed semaglutide 0.5 mg and 1 mg reduced major adverse cardiovascular events by 26% versus placebo [2].

What Ozempic and Insulin Actually Treat

Ozempic is FDA-approved specifically for glycemic control in adults with T2D, and for cardiovascular risk reduction in adults with T2D and established cardiovascular disease [3]. Wegovy (semaglutide 2.4 mg) carries a separate approval for chronic weight management in adults with a BMI <30 or BMI <27 with at least one weight-related condition [4].

Insulin therapy occupies a different clinical tier. It becomes the standard of care when oral agents and GLP-1 agonists fail to bring HbA1c below the patient's individualized target, or when a patient presents with HbA1c above 10% at diagnosis, per the American Diabetes Association's 2024 Standards of Care [5].

The GLP-1 Mechanism in Plain Language

GLP-1 receptor agonists mimic glucagon-like peptide-1, a hormone released from the gut after eating. They slow gastric emptying, reduce appetite signaling in the hypothalamus, and stimulate glucose-dependent insulin secretion. Because the insulin release is glucose-dependent, the hypoglycemia risk is low when GLP-1 agonists are used as monotherapy [5].

Where Insulin Fits

Basal insulin (e.g., insulin glargine, insulin degludec) suppresses hepatic glucose output overnight and between meals. Bolus insulin (e.g., insulin lispro, insulin aspart) covers postprandial glucose spikes. The ADA's 2024 guidance states that combination GLP-1 plus basal insulin is a preferred regimen for patients who need both glycemic control and cardiovascular or renal protection [5]. The SUSTAIN-9 trial (N=302) showed that adding semaglutide 1 mg to basal insulin reduced HbA1c by an additional 1.4 percentage points versus placebo at 30 weeks [6].

Who Qualifies: The Eligibility Criteria a Prescriber Uses

A prescriber evaluating a patient for semaglutide or insulin uses a layered checklist. Meeting one criterion is rarely sufficient on its own.

GLP-1 Agonist Eligibility

The FDA label for Ozempic requires a diagnosis of T2D [3]. Wegovy's label covers adults without diabetes if BMI is <30, or BMI is <27 with at least one of the following: hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease [4].

Contraindications include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), based on rodent carcinogenicity data that prompted an FDA black-box warning [3]. Active pancreatitis is also a contraindication.

A prescriber will typically order:

• Fasting glucose and HbA1c
• Comprehensive metabolic panel (CMP) to check renal and hepatic function
• Lipid panel
• Thyroid-stimulating hormone (TSH) if clinically indicated
• BMI and blood pressure at the point-of-care visit

Insulin Eligibility

Insulin has no BMI threshold. The clinical triggers are:

1. T2D with HbA1c persistently above the individualized target (often <7% per ADA) despite optimized oral agents and/or GLP-1 therapy [5]
2. New-onset T2D presenting with HbA1c above 10% or symptomatic hyperglycemia
3. Type 1 diabetes (T1D), where insulin is mandatory
4. Gestational diabetes uncontrolled by medical nutrition therapy

The ADA notes: "For patients with type 2 diabetes not achieving glycemic goals, basal insulin is often the preferred initial insulin regimen due to its efficacy and lower hypoglycemia risk." [5]

The Step-by-Step Access Pathway for a Regular Patient

Getting a GLP-1 or insulin prescription follows a predictable sequence. The timeline varies by whether the patient goes through a primary care physician, an endocrinologist, or a telehealth provider.

Step 1: Establish a Clinical Relationship

A patient needs a licensed prescriber. This can be a primary care physician, a nurse practitioner, a physician assistant, or a telehealth provider operating in the patient's state. Telehealth platforms can compress the intake-to-prescription timeline to 5 to 14 days if lab work is completed promptly.

Step 2: Complete Required Lab Work

For GLP-1 access, most prescribers require at minimum an HbA1c and fasting glucose. For Wegovy (obesity indication without T2D), some prescribers add a metabolic panel. Labs can be ordered through the telehealth platform's partner lab network or through a local Quest or LabCorp draw site.

Step 3: The Clinical Consultation

The prescriber reviews lab results, medical history, current medications (checking for interactions, particularly with drugs that affect gastric emptying), and contraindications. This visit is typically 20 to 30 minutes via video for telehealth. The prescriber then makes a diagnosis-driven prescribing decision.

Step 4: Prescription and Titration

Ozempic starts at 0.25 mg SC once weekly for 4 weeks, then 0.5 mg, with options to escalate to 1 mg or 2 mg based on glycemic response and tolerability [3]. Wegovy follows a longer titration: 0.25 mg for 4 weeks, escalating every 4 weeks to the maintenance dose of 2.4 mg at week 17 [4].

Basal insulin typically starts at 10 units SC once daily or 0.1 to 0.2 units per kilogram, with titration guided by fasting glucose readings. Self-monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM) is standard practice during titration [5].

Step 5: Insurance Navigation or Cost Alternatives

Novo Nordisk's Ozempic patient savings card can reduce out-of-pocket cost to as low as $25/month for eligible commercially insured patients. Patients without commercial insurance often pay $900, $1,000/month at retail. Wegovy has a separate savings program.

Compounded semaglutide became widely available during the FDA-declared shortage period. The FDA removed semaglutide from its drug shortage list in early 2025, which affects the legal compounding field [7]. Patients should verify their pharmacy's compounding status with their prescriber.

The Evidence Base: Why These Drugs Get Prescribed

Clinical decisions should rest on trial data, not celebrity associations. The evidence for semaglutide is unusually strong across multiple outcomes.

Glycemic Control

The SUSTAIN program (eight phase 3 trials) consistently showed semaglutide 1 mg reducing HbA1c by 1.5 to 1.8 percentage points from baseline versus comparators including sitagliptin, exenatide ER, and insulin glargine [2]. The 2024 ADA Standards of Care list GLP-1 receptor agonists as preferred agents for patients with T2D and established or high cardiovascular risk, independent of baseline HbA1c [5].

Weight Reduction

The STEP trial program specifically evaluated semaglutide 2.4 mg for obesity. STEP-1 (N=1,961, 68 weeks) showed 14.9% mean weight loss versus 2.4% with placebo [1]. STEP-4 (N=803) demonstrated that discontinuing semaglutide at week 20 resulted in regain of approximately two-thirds of the lost weight by week 68, underscoring that this is a chronic, not a short-term, therapy [8].

Cardiovascular Outcomes

The SELECT trial (N=17,604), published in the New England Journal of Medicine in 2023, showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with obesity and established cardiovascular disease but without diabetes [9]. This was the first cardiovascular outcomes trial for a GLP-1 agonist conducted specifically in a non-diabetic population with obesity.

Insulin Outcomes Data

For T2D patients requiring insulin, the DEVOTE trial (N=7,637) compared insulin degludec to insulin glargine U100 and found degludec produced significantly lower rates of severe hypoglycemia (40% lower rate) at similar HbA1c reductions, supporting its place as a preferred basal option [10].

Common Side Effects and How They Are Managed

GLP-1 agonists produce predominantly gastrointestinal side effects. In STEP-1, nausea occurred in 44% of the semaglutide group versus 16% in the placebo group; vomiting in 24% versus 6% [1]. The majority of GI events occurred during the titration phase and resolved or improved with dose maintenance.

Managing GI Effects

Standard clinical guidance includes:

• Eating smaller, lower-fat meals during the first 4 to 8 weeks
• Avoiding lying down within 2 hours of eating
• Staying well-hydrated
• Slowing the titration schedule if nausea is persistent (e.g., extending each dose level by an additional 4 weeks)

Prescribers may also recommend ondansetron or famotidine for acute nausea management during the titration window.

Insulin-Specific Risks

Hypoglycemia is the primary risk with insulin. Patients initiating basal insulin should be counseled on the 15-15 rule for mild-to-moderate hypoglycemia (15 grams of fast-acting carbohydrates, recheck in 15 minutes) and instructed to keep glucagon emergency kits accessible [5]. CGM significantly reduces hypoglycemia risk; a 2022 NEJM study (N=175) showed real-time CGM reduced time below glucose range by 54% compared to finger-stick monitoring alone in insulin-treated T2D patients [11].

Telehealth vs. In-Person: Which Path Is Faster

For most patients without complex comorbidities, telehealth is the faster route to a GLP-1 prescription. The typical timeline:

• Day 1: Complete intake forms and order labs
• Day 3 to 5: Complete blood draw at a local lab site
• Day 5 to 10: Video consultation with prescriber
• Day 7 to 14: Prescription sent to pharmacy

In-person endocrinology referrals average 3 to 6 weeks for a new patient appointment in metropolitan areas, and longer in rural settings, per a 2022 analysis published in JAMA Internal Medicine [12].

Telehealth is not appropriate for all patients. Those with prior pancreatitis, active gallbladder disease, a personal or family history of MEN2, or complex insulin regimens requiring in-person training should establish care with a physician who can conduct a physical examination.

The HealthRX clinical team uses a three-tier intake screen for GLP-1 candidates:

Tier 1 (Telehealth eligible): BMI <30 or T2D with HbA1c 7 to 10%, no contraindications, no prior pancreatitis, stable renal function (eGFR <60 requires endocrinology co-management).

Tier 2 (Telehealth with specialist co-management): eGFR 30 to 60, prior GI surgery, history of eating disorder, or HbA1c above 10% at first presentation.

Tier 3 (In-person only): Personal or family history of MEN2 or medullary thyroid carcinoma, active pancreatitis, T1D requiring basal-bolus insulin regimen adjustment, or pregnancy.

Cost, Insurance, and Affordability

Ozempic and Wegovy are among the most expensive branded medications in the United States. Without insurance, Ozempic retails at approximately $936 per 4-dose pen (1 mg/dose) and Wegovy at approximately $1,349 per 4-pen pack (2.4 mg/dose). These prices fluctuate by pharmacy.

Insurance Coverage Pathways

Medicare Part D covers Ozempic for T2D management but, as of 2024, does not cover Wegovy for obesity. The Inflation Reduction Act provisions allow Medicare to negotiate some drug prices starting in 2026, and semaglutide is on the list of drugs under negotiation.

Commercial insurers vary widely. Prior authorization typically requires documented T2D diagnosis, HbA1c above a threshold (often 7.5% or 8%), and evidence of failure or contraindication to at least one first-line oral agent (usually metformin).

Manufacturer Assistance

Novo Nordisk offers the Ozempic Savings Card (eligible commercially insured patients may pay as low as $25 for a 1-month or 3-month supply) and the NovoCare patient assistance program for uninsured patients meeting income criteria. Applications are available at novonordisk-us.com, though patients should confirm current program terms with their pharmacy or prescriber.

Frequently Asked Questions